Aclaris Therapeutics, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the 2026 Annual Meeting of Stockholders held by Aclaris Therapeutics, Inc. on June 4, 2026. The filing details the voting outcomes for three proposals submitted to shareholders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Of the 139,663,680 shares outstanding, 112,499,671 shares (approximately 80.55%) were present or represented by proxy. The results for the three proposals were as follows:
- Proposal 1 (Election of Directors): Stockholders elected Anand Mehra, M.D., and Maxine Gowen, Ph.D., to serve until the 2029 annual meeting.
- Anand Mehra, M.D.: 83,063,569 votes For; 10,075,624 votes Withheld.
- Maxine Gowen, Ph.D.: 84,209,108 votes For; 8,930,085 votes Withheld.
- Proposal 2 (Advisory Executive Compensation): Stockholders approved the compensation of named executive officers.
- Votes For: 83,370,124
- Votes Against: 9,734,691
- Abstained: 34,378
- Proposal 3 (Ratification of Auditors): Stockholders ratified the selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Votes For: 112,322,811
- Votes Against: 159,714
- Abstained: 17,146
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the definitive proxy statement (Schedule 14A) filed on April 23, 2026, for detailed biographies of the elected directors and executive compensation specifics.
- Confirm the total number of shares outstanding and the record date used for the 80.55% participation rate.
- Note the significant number of broker non-votes (19,360,478) on the director election and executive compensation proposals.
- Review the upcoming fiscal year 2026 financial statements to assess the company's financial health, as this 8-K contains no financial data.